VANCOUVER, BC, Aug. 22, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) highlights the potential of its novel lipid-in-oil delivery platform, DPX™, across multiple infectious disease studies and announces its plans for partnering and further development. BioVaxys’ DPX™ technology (“DPX”) is a patented delivery platform that can incorporate a… Continue reading BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases

Eli Lilly’s weight loss drug, tirzepatide, has demonstrated significant potential in reducing the risk of developing Type 2 diabetes in obese or overweight adults with prediabetes. In a long-term, late-stage trial, participants who received tirzepatide, the active ingredient in both the weight loss drug Zepbound and the diabetes medication Mounjaro, exhibited a 94% lower risk… Continue reading Eli Lilly’s weight loss drug slashes the risk of developing diabetes in long-term trial

Mpox, formerly known as monkeypox, has been addressed by the World Health Organization’s (WHO) regional director for Europe, Dr. Hans Kluge, who emphasized that it is “not the new Covid” and that the risk to the general population remains low. In a statement, Dr. Kluge rejected comparisons between mpox and the coronavirus pandemic, urging global… Continue reading Mpox is ‘not the new Covid’ and the disease can be stopped, WHO director says

MADISON, Wis., Aug. 19, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and SpayVac for Wildlife, Inc. (“SpayVac”) jointly announce that SpayVac® recently completed set-up of its new research and production facility in Madison, Wisconsin to produce their long-lasting, single-dose veterinary contraceptive vaccines. SpayVac® uses a patented liposome-based antigen delivery platform technology, licensed from BioVaxys… Continue reading SPAYVAC FOR WILDLIFE, INC. ANNOUNCES COMPLETION OF SPAYVAC RESEARCH AND PRODUCTION FACILITY IN MADISON, WISCONSIN

VANCOUVER, British Columbia — (Business Wire) —  Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 18/463,157, entitled “Solid Forms… Continue reading Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease

The Biden administration has announced the first 10 prescription drugs that will undergo price negotiations between drugmakers and Medicare, marking a significant milestone aimed at making expensive medications more affordable for older Americans. These negotiations are part of the Inflation Reduction Act, which gave Medicare the authority to negotiate drug prices for the first time… Continue reading Biden administration releases prices of 10 drugs in Medicare negotiations, says U.S. will save $6 billion in first year

VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. (“BioNxt” or the “Company“) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter of intent (the “LOI”) with German-based international contract research, development, and manufacturing company Gen-Plus GmbH & Co KG (“Gen-Plus”), a part of Conscio Group. Further to the Master… Continue reading BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

The direct-to-consumer health-care startup Ro has introduced a new free tool designed to help patients determine their insurance coverage for a class of drugs known as GLP-1s, which are used for weight loss and diabetes management. While most insurance plans cover GLP-1s for diabetes treatment, they are less frequently covered for weight loss, creating confusion… Continue reading Digital health company Ro launches GLP-1 insurance-coverage checker to help patients navigate costs

VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the… Continue reading Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

SUNNYVALE, Calif., Aug. 7, 2024 /PRNewswire/ – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces that it has signed a fully funded strain engineering program (the “Program”) with an innovative Ag-Biotech company in the biopesticides sector. “This is truly an exciting partnership… Continue reading WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY

Vancouver, British Columbia–(Newsfile Corp. – August 7, 2024) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it intends to complete a non-brokered private placement of up to 16,666,666 units (each a “Unit“) at CAD$0.30… Continue reading Optimi Health Announces Non-Brokered Private Placement

The Alzheimer’s drug Leqembi, developed by Eisai in collaboration with Biogen, demonstrated a significant slowing of disease progression in patients over a three-year period, according to new data. This extended study highlights the necessity for long-term treatment, as stopping the drug leads to worsening symptoms. Leqembi, which targets amyloid plaques in the brain—a key factor… Continue reading Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says